The Latest Breaking News from HIV

As lawmakers in Washington debate the new federal budget, one group is bracing for devastating consequences: Americans living with HIV. The proposed GOP-led budget calls...

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the people who need it? Rachel Schraer reports

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

IN FULL

Strategy may lead to new vaccines that only need to be taken once

It's unclear how many people in the US and abroad will get access to the powerful new HIV prevention medication

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

A twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP

IN FOCUS: Without US funding as leverage, one of Uganda’s most prominent LGBT+ activists Steven Kabuye tells Rachel Schraer, there are few ways to push the country towards change